

19th May 2025

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director Dealings

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces that the Board has approved a further eight month extension of the timeline in which Mr Jeremy Randall may exercise the 483,333 share options granted to him on 5th November 2013 such that these options will now lapse on 31st December 2025.

The extension ensures the alignment with the Company's long-term strategic objectives and continuity of leadership during a period of active transformation and growth. As at the time of this announcement, Mr Randall owns 1.72% of the issued share capital of VLG and holds 2,483,333 options.

For further information, please contact:

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cavendish Capital Markets Limited (Nomad and Broker)

+44 (0) 20 7720 0500

Stephen Keys / George Lawson (Corporate Finance)

Michael Johnson (Sales)

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health and Her product range supporting the hormonal lifecycle, the UltraDEX and Dentyl oral care product ranges, products for fungal infections and proctology, and demo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples and are sold in over 90 countries worldwide. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBVLLFEELXBBF